UNSPSC 51144113: Clobenzorex

This classification denotes an anorexiant with the molecular formula C16H18ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4A5352XI2A, chemically known as benzeneethanamine, n-((2-chlorophenyl)methyl)-alpha-methyl-, (+)- but more generally known as clobenzorex, which bears US NIH Compound Identifier 71675. European Medicines Agency schedules Clobenzorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06676MIG.

UNSPSC 51144113 Clobenzorex is a Commodity code that nominally identifies a single pharmaceutical product, yet recent state and local solicitations tagged under this code do not procure clobenzorex specifically. Instead, issuing bodies are buying a broad mix of pharmaceutical products and drug-related systems — naloxone, generic multi-source medications, over-the-counter products, and drug deactivation equipment — through competitive bidding and cooperative purchasing frameworks. The work spans product procurement for public health and pharmacy benefit programs, with vendors required to meet FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act requirements, and standard insurance and employment-eligibility documentation. Issuing bodies include state health departments, county health systems, and cooperative purchasing alliances serving multiple state and local government facilities. The code shows little coherence to clobenzorex itself; the tag appears to reflect a legacy classification or a data-entry misalignment rather than genuine pharmaceutical-category procurement activity.

Geographic activity centers on Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026 response deadline) to gather market intelligence on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, signaling exploratory procurement activity before formal RFP release. The Minnesota Department of Administration, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract awards effective July 1, 2026 and a 3 percent administrative fee structure. Vendors on the MMCAP contract must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and comply with a 75 percent price-competitiveness evaluation weighting.